top of page

BIO 2026: Nkarta will have key data by the end of the year from its NK cell therapy approach in a host of autoimmune conditions

  • 2 hours ago
  • 1 min read

CEO Paul Hastings describes his opinion of the benefits of an NK cell approach over T-cells, and discusses the work Nkarta has done to get to a high dose that should tell a clear story of the profile of this by year end.




Coverage brought to you by



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter
  • LinkedIn
  • Facebook
  • TikTok
  • Instagram

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

10x_Genomics_logo.svg.png

10x Genomics delivers powerful, reliable tools that fuel scientific discoveries and drive exponential progress to master biology to advance human health. Cited in more than 10,000 research papers, our innovative single cell, spatial, and in situ technologies enable discoveries across oncology, immunology, neuroscience, and more.

 

Our talented, dedicated science professionals have a distinguished record of creating innovative instruments, reagents, and software that analyze biological systems at a resolution that matches the complexity of biology.

bottom of page